Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). (2005)

Peer-Reviewed Study · Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, Schinkel AH · 2005

Merino G et al., 2005: Cell-line study of how benzimidazoles interact with human efflux transporters. Oxfendazole, the active metabolite, is a substrate and inhibitor of BCRP/ABCG2, while fenbendazole itself was not a substrate of murine Bcrp1, P-glycoprotein or MRP2.

ABZSO and OXF were transported efficiently by murine Bcrp1 and moderately by human BCRP, but not by MDR1 or MRP2.

Merino G et al., 2005: Cell-line study of how benzimidazoles interact with human efflux transporters. Oxfendazole, the active metabolite, is a substrate and inhibitor of BCRP/ABCG2, while fenbendazole itself was not a substrate of murine Bcrp1, P-glycoprotein or MRP2. In vitro transporter study (MDCKII cells transduced with human MDR1, MRP2, BCRP and murine Bcrp1); no patients; Netherlands (Netherlands Cancer Institute). Funder: Dutch national research support. Declared conflicts: none recorded. Comparator: vector-transfected control cells. Relevant to C5 because BCRP is expressed in gut and liver and is the transporter that limits oral absorption of many drugs; it also links to the cancer literature, where BCRP expression is a resistance mechanism. Study type: lab.